Clinical Trial Results:
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection
Summary
|
|
EudraCT number |
2017-002156-84 |
Trial protocol |
SE LV LT FR DE SK BE CZ NL ES HU BG PL GB AT IT Outside EU/EEA |
Global end of trial date |
26 May 2020
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 Mar 2021
|
First version publication date |
13 Mar 2021
|
Other versions |
|
Summary report(s) |
63623872FLZ3001 (2017-002156-84)_Limited Results |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
63623872FLZ3001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03376321 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Janssen Research & Development, LLC
|
||
Sponsor organisation address |
920 Route 202, Raritan, United States, NJ 08869
|
||
Public contact |
Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com
|
||
Scientific contact |
Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-001975-PIP01-16 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
26 May 2020
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
26 May 2020
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective is to evaluate superiority of pimodivir in combination with standard-of-care (SOC) treatment compared to placebo in combination with SOC treatment on Day 6, with respect to the clinical outcome on the hospital recovery scale.
|
||
Protection of trial subjects |
Safety assessments included AE, laboratory parameters, electrocardiogram [ECG], vital signs, and National Early Warning Score [NEWS2]).
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
20 Dec 2017
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Canada: 1
|
||
Country: Number of subjects enrolled |
Netherlands: 3
|
||
Country: Number of subjects enrolled |
Poland: 24
|
||
Country: Number of subjects enrolled |
Slovakia: 1
|
||
Country: Number of subjects enrolled |
Spain: 24
|
||
Country: Number of subjects enrolled |
Sweden: 16
|
||
Country: Number of subjects enrolled |
United Kingdom: 1
|
||
Country: Number of subjects enrolled |
Austria: 18
|
||
Country: Number of subjects enrolled |
Belgium: 2
|
||
Country: Number of subjects enrolled |
Bulgaria: 10
|
||
Country: Number of subjects enrolled |
France: 9
|
||
Country: Number of subjects enrolled |
Germany: 1
|
||
Country: Number of subjects enrolled |
Italy: 4
|
||
Country: Number of subjects enrolled |
Latvia: 3
|
||
Country: Number of subjects enrolled |
Lithuania: 4
|
||
Country: Number of subjects enrolled |
Israel: 36
|
||
Country: Number of subjects enrolled |
Brazil: 3
|
||
Country: Number of subjects enrolled |
Vietnam: 1
|
||
Country: Number of subjects enrolled |
United States: 36
|
||
Country: Number of subjects enrolled |
Malaysia: 21
|
||
Country: Number of subjects enrolled |
India: 18
|
||
Country: Number of subjects enrolled |
Ukraine: 14
|
||
Country: Number of subjects enrolled |
Russian Federation: 1
|
||
Country: Number of subjects enrolled |
South Africa: 17
|
||
Country: Number of subjects enrolled |
Australia: 2
|
||
Country: Number of subjects enrolled |
Argentina: 9
|
||
Country: Number of subjects enrolled |
Turkey: 8
|
||
Country: Number of subjects enrolled |
Mexico: 12
|
||
Country: Number of subjects enrolled |
Singapore: 2
|
||
Country: Number of subjects enrolled |
Chile: 1
|
||
Country: Number of subjects enrolled |
New Zealand: 1
|
||
Country: Number of subjects enrolled |
Taiwan: 1
|
||
Country: Number of subjects enrolled |
Thailand: 22
|
||
Worldwide total number of subjects |
326
|
||
EEA total number of subjects |
119
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
4
|
||
Adults (18-64 years) |
192
|
||
From 65 to 84 years |
130
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
- | ||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
Overall, 334 subjects were randomized, of which 326 (97.6%) subjects were treated (and included in the Safety Set). | ||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
Overall Period
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||
Roles blinded |
Investigator, Subject | ||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
Pimodivir + SOC | ||||||||||||||||||||||||
Arm description |
Subjects received pimodivir 600 milligram (mg) orally twice daily for 5 days (on Days 1 through 5; for subjects who received only 1 dose of pimodivir on Day 1 [evening], dosing continued until the morning of Day 6) along with SOC treatment. | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
Pimodivir
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
Pimodivir was administered.
|
||||||||||||||||||||||||
Arm title
|
Placebo + SOC | ||||||||||||||||||||||||
Arm description |
Subjects received placebo matching to pimodivir orally twice daily for 5 days (on Days 1 through 5; for subjects who received only 1 dose of placebo on Day 1 [evening], dosing continued until morning of Day 6) along with SOC treatment. | ||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
Placebo was administered.
|
||||||||||||||||||||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Pimodivir + SOC
|
||
Reporting group description |
Subjects received pimodivir 600 milligram (mg) orally twice daily for 5 days (on Days 1 through 5; for subjects who received only 1 dose of pimodivir on Day 1 [evening], dosing continued until the morning of Day 6) along with SOC treatment. | ||
Reporting group title |
Placebo + SOC
|
||
Reporting group description |
Subjects received placebo matching to pimodivir orally twice daily for 5 days (on Days 1 through 5; for subjects who received only 1 dose of placebo on Day 1 [evening], dosing continued until morning of Day 6) along with SOC treatment. |
|
||||||||||||||||||||||||||||
End point title |
Hospital Recovery Scale on Day 6 | |||||||||||||||||||||||||||
End point description |
The hospital recovery scale assesses a participant's clinical status. The scale provides 6 mutually exclusive conditions ordered from best to worst: 1) not hospitalized; 2) non-ICU hospitalization, not requiring supplemental oxygen (SO); 3) non-ICU hospitalization, requiring supplemental oxygen; 4) admitted to the ICU, not requiring invasive mechanical ventilation (IMV); 5) requiring invasive mechanical ventilation; and 6) death.
|
|||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||
End point timeframe |
Day 6
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Statistical analysis title |
Statistical Analysis | |||||||||||||||||||||||||||
Comparison groups |
Placebo + SOC v Pimodivir + SOC
|
|||||||||||||||||||||||||||
Number of subjects included in analysis |
318
|
|||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||||||||
Analysis type |
other | |||||||||||||||||||||||||||
P-value |
= 0.366 | |||||||||||||||||||||||||||
Method |
Van Elteren test | |||||||||||||||||||||||||||
Confidence interval |
|
||||||||||||||||
Adverse events information [1]
|
||||||||||||||||
Timeframe for reporting adverse events |
Up to 33 days
|
|||||||||||||||
Assessment type |
Systematic | |||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||
Dictionary version |
22.1
|
|||||||||||||||
Reporting groups
|
||||||||||||||||
Reporting group title |
Pimodivir + SOC
|
|||||||||||||||
Reporting group description |
- | |||||||||||||||
Reporting group title |
Placebo+SOC
|
|||||||||||||||
Reporting group description |
- | |||||||||||||||
|
||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||
|
||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: No adverse events reported |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
02 Mar 2018 |
The overall reason was to implement the recommendations from specific Health Authorities. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
The limited results for this early terminated trial are available in the attached CSR synopsis. |